Nucleic Acid Preparations Identify Norovirus and Mycoplasma pneumonia
|
By LabMedica International staff writers Posted on 15 Oct 2013 |

Image: DiaSorin's LIAISON IXT for the purification of nucleic acids (Photo courtesy of Diasorin).
Extraction kits provide high yield, high purity nucleic acid preparations for sensitive and accurate molecular identification of Norovirus and Mycoplasma pneumonia.
Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.
The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.
Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.
During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.
In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.
Related Links:
DiaSorin
Magnetic bead technology extraction kits concentrates target microorganisms from a variety of sample matrices, including urine, sputum, culture, and swabs, and then provides a purified nucleic acid extraction for downstream molecular analysis. No enzymatic pretreatment or prior heat treatment is required.
The DiaSorin (Saluggia, Italy) BUGS’n Beads nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
Outbreaks of Norovirus, also known as winter vomiting disease, can spread quickly in certain semiclosed environments and frequently cause ward closures in hospitals during the winter months. Human noroviruses cannot be grown in cell culture and so diagnostic methods focus on the detection of viral RNA or antigen.
Mycoplasma pneumonia is a common cause of atypical pneumonia. Since other, less common etiological agents exist, which require a different course of treatment, identification of bacterial DNA in clinical samples has become increasingly important in establishing the cause of atypical pneumonia so that the optimal directed therapy can be provided for patients.
During winter, clinical laboratories experience an increase in test requests for certain seasonal pathogens such as Norovirus and Mycoplasma pneumonia. The DiaSorin nucleic acid extraction kits, for use with the automated DiaSorin LIAISON IXT/Arrow instruments, provide a highly purified nucleic acid preparation from patient samples for sensitive and accurate molecular confirmation of these microorganisms.
DiaSorin BUGS’n Beads can be used for the extraction of nucleic acid from a variety of pathogens, including Mycobacterium tuberculosis, Enterovirus, MRSA, Norovirus, Escherichia coli, Legionella, Mycoplasma pneumonia, Chlamydia pneumonia, and Helicobacter pylori.
In addition to BUGS’n Beads, DiaSorin nucleic acid extraction kits are available for the extraction of RNA or DNA, the extraction of DNA from stool and blood samples, and cell separation.
Related Links:
DiaSorin
Latest Technology News
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Channels
Clinical Chemistry
view channel
Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read moreMolecular Diagnostics
view channel
Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read morePathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







